These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38578630)

  • 1. WHO Documents Rising Resistance to First-Line HIV Drug.
    Harris E
    JAMA; 2024 Apr; 331(16):1355. PubMed ID: 38578630
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolution of primary HIV drug resistance in a subtype C dominated epidemic in Mozambique.
    Bila DC; Young P; Merks H; Vubil AS; Mahomed M; Augusto A; Abreu CM; Mabunda NJ; Brooks JI; Tanuri A; Jani IV
    PLoS One; 2013; 8(7):e68213. PubMed ID: 23935858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the HIV drug resistance surveillance system in Mozambique, 2017-2018.
    Nuvunga S; Langa DC; Baltazar CS; Sacarlal J; Rossetto E; Vubil A
    Pan Afr Med J; 2022; 43():162. PubMed ID: 36825120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
    Gibson RM; Nickel G; Crawford M; Kyeyune F; Venner C; Nankya I; Nabulime E; Ndashimye E; Poon AFY; Salata RA; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
    Infect Dis Poverty; 2017 Dec; 6(1):163. PubMed ID: 29202874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society.
    Havlir D; Vella S; Hammer S
    AIDS; 2002 Jul; 16(10):7-9. PubMed ID: 12146462
    [No Abstract]   [Full Text] [Related]  

  • 6. Estimating HIV pre-exposure prophylaxis need and impact in Malawi, Mozambique and Zambia: A geospatial and risk-based analysis.
    Stelzle D; Godfrey-Faussett P; Jia C; Amiesimaka O; Mahy M; Castor D; Hodges-Mameletzis I; Chitembo L; Baggaley R; Dalal S
    PLoS Med; 2021 Jan; 18(1):e1003482. PubMed ID: 33428611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Immunodeficiency Virus (HIV) Drug Resistance in African Infants and Young Children Newly Diagnosed With HIV: A Multicountry Analysis.
    Jordan MR; Penazzato M; Cournil A; Vubil A; Jani I; Hunt G; Carmona S; Maphalala G; Mthethwa N; Watera C; Kaleebu P; Musanhu CC; Mtapuri-Zinyowera S; Dzangare J; Peeters M; Yang C; Parkin N; Bertagnolio S
    Clin Infect Dis; 2017 Nov; 65(12):2018-2025. PubMed ID: 29020335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrepancies between WHO 2009 and IAS-USA 2009 lists for determining the rate of transmitted HIV-1 drug resistance: a prospective study.
    Sungkanuparph S; Kiertiburanakul S; Sukasem C; Chantratita W
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):e3-5. PubMed ID: 22156823
    [No Abstract]   [Full Text] [Related]  

  • 9. Global HIV drug resistance surveillance.
    De Felici A
    Scand J Infect Dis Suppl; 2003; 106():21-3. PubMed ID: 15000577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
    Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Epidemiology and Trends in HIV-1 Transmitted Drug Resistance in Mozambique 1999-2018.
    Ismael N; Wilkinson E; Mahumane I; Gemusse H; Giandhari J; Bauhofer A; Vubil A; Mambo P; Singh L; Mabunda N; Bila D; Engelbrecht S; Gudo E; Lessells R; de Oliveira T
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
    Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF;
    Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility to etravirine of HIV type 1 subtype C isolates from nevirapine/efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
    Anquetil D; Deshpande A; Zongo D; Le Bihan L; Pinson PR; Fleury HJ
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1793-7. PubMed ID: 22519709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.
    Machnowska P; Hauser A; Meixenberger K; Altmann B; Bannert N; Rempis E; Schnack A; Decker S; Braun V; Busingye P; Rubaihayo J; Harms G; Theuring S
    PLoS One; 2017; 12(5):e0178297. PubMed ID: 28562612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV drug resistance and you. Resistance testing in experienced patients. Considerations when changing drugs.
    Posit Aware; 2006; Spec No():17-22. PubMed ID: 16596730
    [No Abstract]   [Full Text] [Related]  

  • 18. Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria.
    Ugbena R; Aberle-Grasse J; Diallo K; Bassey O; Jelpe T; Rottinghaus E; Azeez A; Akpan R; Muhammad M; Shanmugam V; Singh S; Yang C
    Clin Infect Dis; 2012 May; 54 Suppl 4():S375-80. PubMed ID: 22544206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abstracts of the XVII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, June 10-14, 2008, Sitges, Spain.
    Antivir Ther; 2008; 13(4):P1-4, A3-178. PubMed ID: 18785335
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.
    Ismael N; Bila D; Mariani D; Vubil A; Mabunda N; Abreu C; Jani I; Tanuri A
    AIDS Res Hum Retroviruses; 2014 Jun; 30(6):603-9. PubMed ID: 24188582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.